Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: kha vu who wrote (21084)	5/19/1998 10:02:00 AM
From: bob smith	Read Replies (1) \| Respond to of 32384

Here is Juback's update on Ligand (5/19/98): Updates New Developments on Past Columns Stocking up on Biotech Michael Murphy, editor of the California Technology Stock Letter, picked Ligand Pharmaceuticals (LGND) as one of his favorite biotech stocks at the lunchtime technology investing panel at the recent Money Show in Las Vegas. By Murphy's count, the company has 39 drugs in the pipeline that should be ready for Food & Drug Administration approval sometime in the next three years.